In the current report, we have focused on in vivo studies in the mouse xenotransplant model to support the notion that this approach should become amenable to monitor response to inhibition of BTK and, prospectively, other kinase inhibitors in patients with lymphoma and, possibly, other malignancies. The gene discussed is BTK; the disease is lymphoma.